Madrigal Pharmaceuticals stock price target raised by Oppenheimer to $590
PositiveFinancial Markets

Madrigal Pharmaceuticals has received a significant boost as Oppenheimer raised its stock price target to $590. This optimistic outlook reflects confidence in Madrigal's innovative therapies and potential market impact, which could attract more investors and enhance the company's growth prospects.
— Curated by the World Pulse Now AI Editorial System